Research programme: respiratory syncytial virus infections therapy - Aviragen Therapeutics

Drug Profile

Research programme: respiratory syncytial virus infections therapy - Aviragen Therapeutics

Alternative Names: BTA-C286; BTA-RSV2; BTA-RSV3

Latest Information Update: 11 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biomolecular Research Institute; Biota Holdings
  • Developer Aviragen Therapeutics
  • Class Small molecules
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Respiratory syncytial virus infections

Most Recent Events

  • 07 Jul 2016 Aviragen Therapeutics and the Georgia State University Research Foundation agree to develop and commercialise antiviral therapeutics in for Respiratory synctial virus infections
  • 12 Apr 2016 Biota Pharmaceuticals is now called Aviragen Therapeutics
  • 30 Jun 2014 Preclinical trials in Respiratory syncytial virus infections in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top